847 karma · joined March 3, 2011
Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., Watkinson, P., Khunti, K., Harnden, A., Coupland, C. A. C., Channon, K. M., Mills, N. L., Sheikh, A., & Hippisley-Cox, J. (2021). Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine. https://doi.org/10.1038/s41591-021-01630-0
Specifically follow this figure: https://www.nature.com/articles/s41591-021-01630-0/figures/1
Basically the risk is higher for people under 40.
In that cohort, risk is highest with the Moderna vaccine within 1-7 days following first and second dose. The risk is higher with the 2nd Moderna dose as compare to Pfizer one. I suspect it may be due to dosing.
Risk is also present with the Pfizer does but more so with the 2nd dose.
Covid-19 itself can also cause Myocarditis.
"The risks are more evenly balanced in younger persons aged up to 40 years, where we estimated the excess in myocarditis events following SARS-CoV-2 infection to be 10 per million with the excess following a second dose of mRNA-1273 vaccine being 15 per million."
Overall, the risk is non-zero but very low compare to actual background rate of myocarditis.
"The incidence of myocarditis is approximately 1.5 million cases worldwide per year. Incidence is usually estimated between 10 to 20 cases per 100,000 persons." Quoted from Kang, M., & An, J. (2021). Viral Myocarditis. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK459259/
So we have 1.5 cases per 100,000 (Moderna vaccine) vs 10-20 per 100,000 (Background).
Python also got heavyweight libraries such as Numpy and Pandas which put it in the front. Perl do not have have such well known libraries as far as I know.
I think non-techie people are more accustomed to "exclusiveness" where you just reach the app directly as compare to having the choice the entering the webpage address or even clicking a bookmark. Sometimes it is more about human psychology than technical issues.
Koutsovoulos, G., Kumar, S., Laetsch, D. R., Stevens, L., Daub, J., Conlon, C., Maroon, H., Thomas, F., Aboobaker, A. A., & Blaxter, M. (2016). No evidence for extensive horizontal gene transfer in the genome of the tardigrade Hypsibius dujardini. Proceedings of the National Academy of Sciences, 113(18), 5053–5058. https://doi.org/10.1073/pnas.1600338113
Maayan, H., Kirgner, I., Gutwein, O., Herzog-Tzarfati, K., Rahimi-Levene, N., Koren-Michowitz, M., & Blickstein, D. (n.d.). Acquired Thrombotic Thrombocytopenic Purpura: A rare disease associated Acquired with BNT162b2 vaccine. Journal of Thrombosis and Haemostasis, n/a(n/a). https://doi.org/10.1111/jth.15420
Yocum, A., & Simon, E. L. (2021). Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. The American Journal of Emergency Medicine. https://doi.org/10.1016/j.ajem.2021.05.001
"Although this is not the case of the authorized COVID-19 mRNA vaccines, future formulations containing adjuvant like TLR agonists [13] may exacerbate pre-existing autoimmune or autoinflammatory disorders and should therefore be discouraged in this cohort of patients."
I guess this mostly relates to the "packaging" of the mRNA vaccines relating to the entry in the cells.